Upadacitinib improves symptoms of ulcerative colitis as early as day one of initiation

The key findings of this study were:

988 individuals (328 placebo, 660 upadacitinib) were examined in total. 

Between days 1 and 3, patients using upadacitinib saw substantial reductions in all UC symptoms compared to placebo, which persisted until day 14. 

75.7% and 48.2% of patients, respectively, exhibited a >50% decrease in hs-CRP and FCP levels from baseline (P .001 vs placebo). 

Significant improvements in QoL were seen at weeks 2 and 8, as well as increased rates of clinical remission/response per Partial Mayo score starting at week 2 (26.9%/59.4% upadacitinib 45 mg QD vs. 4.3%/22.3% placebo, P .001). 

Clinical remission/response at week 8 was significantly correlated with early improvements in stool frequency and bowel urgency by day 3, as well as decreases in hs-CRP and FCP by week 2.

Reference: 

Loftus, E. V., Jr., Colombel, J.-F., Takeuchi, K., Gao, X., Panaccione, R., Danese, S., Dubinsky, M., Schreiber, S., Ilo, D., Finney-Hayward, T., Zhou, W., Phillips, C., Gonzalez, Y. S., Shu, L., Yao, X., Zhou, Q., & Vermeire, S. (2022). Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment. In Clinical Gastroenterology and Hepatology. Elsevier BV. https://doi.org/10.1016/j.cgh.2022.11.029